European Regulators Recommend Olumiant for Adolescent Alopecia Areata Treatment
核心洞察
The European Medicines Agency (搜索)'s CHMP issued a positive opinion for Olumiant (baricitinib) to treat severe alopecia areata (搜索) in adolescents aged 12 to under 18 years.
The recommendation is based on Phase 3 BRAVE-AA-PEDS study data showing 42% of patients achieved 80% or more scalp hair coverage at 36 weeks.
This represents the first and largest clinical trial specifically designed to evaluate severe alopecia areata (搜索) treatment in children and adolescents.
The European Medicines Agency (搜索)'s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) to treat severe alopecia areata (搜索) in adolescents aged 12 to under 18 years, marking a significant advancement in pediatric dermatology treatment options. The recommendation is now referred to the European Commission for final approval, with a decision expected within one to two months.
Breakthrough Clinical Trial Results
The positive opinion is supported by data from the Phase 3 BRAVE-AA-PEDS study, which demonstrated that 42% of patients with severe alopecia areata (搜索) achieved 80% or more scalp hair coverage at 36 weeks. This represents the first and largest clinical trial specifically designed to evaluate children and adolescents with severe alopecia areata, addressing a critical gap in treatment options for young patients.
"The positive CHMP opinion supports the potential expansion of Olumiant as a new treatment option for adolescents living with the profound physical and emotional realities of severe alopecia areata (搜索)," said Anabela Cardoso, senior vice president, Lilly Immunology Medical Affairs.
The BRAVE-AA-PEDS trial enrolled 257 adolescent participants in its first cohort, who were randomized in a 1:1:1 ratio to receive once-daily placebo, Olumiant 4 mg, or Olumiant 2 mg. The primary endpoint was achieving a SALT score ≤20, representing 80% or more scalp hair coverage at Week 36. A second cohort of 166 adolescents was randomized 1:1 to Olumiant 4 mg or 2 mg to accumulate additional safety data.
Addressing Unmet Medical Needs
Alopecia areata (搜索) is a chronic immune disease that can have devastating social and emotional impacts on young patients and their families. Early onset alopecia areata can be more severe and lead to extensive and unpredictable hair loss, making effective treatment particularly crucial for adolescent patients.
"Adolescents with severe alopecia areata (搜索) represent a particularly vulnerable population, as the disease is difficult to manage and occurs at a time when appearance can have a significant impact on social identity and emotional well-being," said Thierry Passeron, M.D., PhD, professor and chair, Department of Dermatology, Université Côte d'Azur.
The safety profile of Olumiant in adolescents with alopecia areata (搜索) was consistent with the safety profile observed in clinical trials for children with juvenile idiopathic arthritis and moderate-to-severe atopic dermatitis. Additionally, 52-week efficacy and safety data demonstrating successful hair regrowth on the scalp, eyebrows, and eyelashes in adolescent patients were presented at the Fall Clinical Dermatology Conference in October 2025.
Regulatory Progress and Market Access
Olumiant, a once-daily oral JAK (搜索) inhibitor discovered by Incyte and licensed to Lilly, received approval from the European Commission and U.S. Food and Drug Administration in 2022 for adult patients with severe alopecia areata (搜索), making it the first JAK inhibitor approved in these regions for severe disease. Lilly has also submitted Olumiant in the U.S. for approval to treat severe alopecia areata in adolescents, with a decision expected in the second half of 2026.
In Canada, Ontario has become the first province to add Olumiant for severe alopecia areata (搜索) to its public drug formulary, representing the first and only treatment for adult patients with severe alopecia areata available through public coverage. This follows successful negotiations between Lilly and the pan-Canadian Pharmaceutical Alliance, which concluded with a letter of intent on November 10, 2025.
"We applaud Ontario for taking the lead in giving people with alopecia areata (搜索) access to an effective treatment option, Olumiant," said Mathilde Merlet, President and General Manager of Lilly Canada.
Clinical Impact and Future Directions
Olumiant is the most-researched JAK (搜索) inhibitor in alopecia areata (搜索), with more than 14,600 patients having received the treatment across all indications in completed and ongoing clinical trials. Of these, over 1,200 have been children and adolescents, providing substantial safety and efficacy data for pediatric populations.
The BRAVE-AA-PEDS study continues with a third cohort consisting of children ages 6 to under 12 years, who will be randomized in a 1:1:1 ratio to receive once-daily placebo, Olumiant high dose, or Olumiant low dose, further expanding the potential treatment population.
"This development offers a ray of hope to our community members who live with the devastating impact of severe alopecia areata (搜索)," said Carolynne Harrison, President of the Canadian Alopecia Areata Foundation. "We eagerly await nationwide access to Olumiant and look forward to empowered futures for individuals and families affected by alopecia areata."